GHRP-2

GHRP-2, or pralmorelin, is a synthetic six-amino-acid growth hormone secretagogue. It releases GH more strongly than GHRP-6 while stimulating appetite less. Clinical investigations use it in diagnosing GH deficiency and examining body composition. Japan has approved Pralmorelin KM as a diagnostic agent for GH deficiency; therapeutic use has no US approval.

• Growth Hormone Support

  Most effective

  Pituitary signaling stimulates the body’s own release of growth hormone.

• Body Composition

  Effective

  Potential changes include more lean tissue and less body fat.

• Recovery & Repair

  Effective

  Research examines support for tissue healing and recovery after injury or exercise.

• Sleep Quality

  Moderate

  Some protocols suggest deeper slow-wave sleep and more restorative rest.

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

• Insulin / IGF-1

  Monitor

• Corticosteroids

  Caution

• Thyroid Hormones

  Monitor

• BPC-157

  Compatible

• TB-500

  Compatible

• Ipamorelin + CJC-1295

  Compatible

  The combination is used for complementary GH stimulation; compatibility is not established by a cited interaction study.

• Somatostatin Analogs

  Avoid

Diluent: Use bacteriostatic water only. Avoid saline because it can cause precipitation.

1. Take the GHRP-2 vial out of refrigeration and wait 15–20 minutes for it to reach room temperature.
2. Disinfect the rubber stopper with an alcohol swab, then let it dry fully in the air.
3. Use a sterile syringe to measure the calculated amount of bacteriostatic water. Use BAC water only; avoid saline because precipitation can occur.
4. Direct the water slowly onto the inner vial wall rather than onto the powder.
5. Rotate the vial gently to mix. Never shake it vigorously; this can degrade the peptide.
6. Wait 2–3 minutes for complete dissolution, and check that the liquid is transparent and colorless.
7. Measure your calculated dose into an insulin syringe for a subcutaneous injection.
8. Choose the abdomen, thigh or upper arm for injection. Change the site each time to help prevent lipodystrophy.
9. Refrigerate the mixed vial at 2–8 °C and use it within 28 days.

Week 1–2

Sleep may begin improving, while mild fluid retention can occur early.

Week 2–4

Sleep may deepen and recovery may improve, with a slight increase in appetite.

Week 4–8

Changes in body composition, energy levels and recovery speed may become noticeable.

Week 8–12

Skin may improve as lower body fat and increased lean mass become more visible.

Week 12+

Body composition, strength and overall vitality may show sustained improvements.

• Fluid retention and slight bloating, particularly at the start of a protocol
• Greater appetite, especially with GHRP compounds
• Warmth or flushing around the injection site
• Numbness or tingling; higher doses can cause symptoms resembling carpal tunnel syndrome
• Tiredness or lethargy when dose timing is unsuitable
• Possible increases in cortisol and prolactin, particularly with GHRP-6
• Higher blood glucose; monitor glucose if you have diabetes or prediabetes · Rare

GHRP-2: not approved in the US.

• US

  Not approved

  FDA — no approval; research use only. No 503A ban is recorded; affirmative compounding authorization remains unestablished.

  Rx required

  No

  Telehealth

  N/A

1. GHRP-2: a GH secretagogue for clinical use (1997)

2. Growth hormone-releasing peptides: clinical applications (2008)